Ketamine Research and Policy Updates
News, research, FDA/DEA policy, and trial updates with patient-facing context on what changes mean for ketamine care.
Have a question about this topic?
Use the contact page when you need to send feedback, request a correction, or ask about the resource.
Featured
3 articlesFDA Ketamine Crackdown: What Patients Should Know
FDA enforcement against illegal ketamine sellers is rising. Learn what this means for patients vetting legitimate telehealth ketamine providers.
Ketamine Eases Resistant Depression and Suicidal Ideation
New research highlights ketamine's promise for treatment-resistant depression and suicidal thoughts. What patients considering ketamine care should know.
NRx Gets FDA Expanded Access for Ketamine Protocol
NRx Pharmaceuticals received FDA Expanded Access for its ketamine-based protocol. Here's what this means for patients pursuing treatment for severe depression.
Brain Scans Could Predict Ketamine Success in Depression
New research shows brain imaging may predict which depression patients will respond best to ketamine therapy, advancing personalized treatment.
Ketamine Study Shows Depression Relief Within Hours
New research confirms single ketamine infusion provides rapid depression relief. What this means for online treatment options.
Ketamine Offers Fast Relief for Depression and Suicidal Thoughts
Medscape research confirms ketamine rapidly relieves depression and suicidal ideation. What it means for patients exploring online ketamine treatment.
Ketamine vs. TMS: Choosing the Right Depression Path
Medical Daily breaks down when ketamine or TMS is the right call for treatment-resistant depression and what patients can realistically expect.
New Trial: CBT After Esketamine Lowers Relapse Risk
CBT-ENDURE trial: pairing CBT with esketamine significantly reduces depression relapse and suicidal ideation. What online ketamine patients need to know.
CBT After Ketamine Cuts Relapse Risk, Trial Finds
The CBT-ENDURE trial shows adding 16 weeks of CBT after esketamine significantly improves outcomes for depression and suicidal ideation. What patients should know.
Your Antidepressant May Not Affect Ketamine Outcomes
New research finds concurrent antidepressant use doesn't significantly alter ketamine or esketamine outcomes — here's what that means for patients.
Ketamine Side Effects Data: What TRD Patients Need to Know
New clinical analysis urges smarter ketamine protocols for TRD—what side effect data and dropout rates mean for patients exploring online ketamine treatment.
What New NMDA Data Means for Ketamine Patients
New clinical guidance on NMDA receptor antagonists urges smarter dose optimization and faster switching. Here's what it means for online ketamine patients.
NMDA Antagonists for TRD: What the Data Means for You
New clinical data on NMDA receptor antagonists for TRD highlights side effect profiles, dropout rates, and why faster dose optimization matters for patients.
When Clinicians Switch Sooner: New TRD Dosing Guidance
New clinical guidance urges faster dose adjustments and PHQ-9 tracking for ketamine patients. Here's what it means for your online treatment.
Faster TRD Remission: What Smarter Dosing Means for You
New clinical guidance on treatment-resistant depression highlights why symptom tracking and dose flexibility matter—especially for online ketamine patients.
What Side Effect Data Means for Ketamine Patients
New research in Psychiatric Times breaks down side effect profiles and dropout rates for ketamine and esketamine. Here's what it means for your treatment decision.
Nitrous Oxide for Depression: What Patients Should Know
New research explores nitrous oxide for treatment-resistant depression. Here's how it compares to ketamine and what it means for patients seeking relief in 2026.
What New TRD Data Means for Ketamine Patients
New clinical guidance on NMDA receptor antagonists urges faster dose optimization and closer monitoring. Here's what it means for online ketamine treatment.
Trump's Psychedelic EO: What It Means for Ketamine Patients
President Trump's 2026 executive order on psychedelic research signals new federal support for ketamine therapy. Here's what online patients need to know.
What Ketamine's Side Effect Data Means for You
New clinical guidance on NMDA antagonist side effects and discontinuation rates has direct implications for patients pursuing ketamine therapy online.
What New NMDA Data Means for Your Ketamine Care
New clinical guidance on ketamine and esketamine side effect tracking is reshaping how providers manage treatment-resistant depression. Here's what it means for you.
Glutamate Treatments Reshape TRD Care in 2026
New research confirms glutamate-based treatments like esketamine offer fast relief for treatment-resistant depression. Here's what it means for online ketamine care.
New Research on Ketamine Side Effects and What It Means
New clinical data on NMDA antagonist side effects and discontinuation rates reveals what telehealth ketamine patients should expect from accountable providers.
AI Prescribing Psych Meds: What It Means for Ketamine Care
A Utah AI prescribing pilot raises safety questions. Here's what it means for ketamine telehealth patients seeking safe, supervised online treatment.
How Doctors Choose TRD Treatments in 2026
New guidance on TRD treatment selection highlights ketamine's role alongside esketamine and brain stimulation. What patients need to know before choosing care.
Esketamine's Role in Treatment-Resistant Depression Care
Comparing ketamine-based options for treatment-resistant depression in 2026: how esketamine differs from generic ketamine and what to ask before choosing.
New PTSD Prevention Drug Trial: What It Means for Patients
A new DoD-backed Phase 2a trial tests BXCL501 for acute stress reactions. Here's what it means for ketamine patients seeking PTSD treatment in 2026.
Why 'Good Enough' Depression Care Is No Longer Enough
New clinical guidance pushes for true remission in treatment-resistant depression. Here's what that means for patients exploring ketamine therapy.
BPL-003 Trial Results: What They Mean for TRD Patients
New phase 2a data on BPL-003 shows lasting depression symptom reduction. Here's what it means for patients exploring ketamine and emerging TRD therapies.
New PTSD Prevention Drug Trial: What Patients Should Know
A new DoD-backed trial is testing BXCL501 for acute stress reactions. Here's what it means for ketamine patients pursuing PTSD treatment today.
Beyond 'Less Bad': New Push for True TRD Remission
Psychiatrists are shifting TRD goals from symptom reduction to full remission. Here's what that means for patients and ketamine therapy in 2026.